Zhejiang Gongdong Medical Technology Co., Ltd. (SHA:605369)
China · Delayed Price · Currency is CNY 22.50
+1.17 (5.49%)
May 8, 2026, 3:00 PM CST
SHA:605369 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,140 | 1,116 | 1,100 | 955.61 | 1,459 | 1,188 |
Other Revenue | 19.96 | 19.96 | 15.02 | 19.47 | 9.25 | 5.85 |
| 1,160 | 1,136 | 1,115 | 975.08 | 1,469 | 1,194 | |
Revenue Growth (YoY) | 4.70% | 1.84% | 14.37% | -33.61% | 22.98% | 43.95% |
Cost of Revenue | 846.54 | 830.4 | 752.09 | 661.42 | 894.14 | 668.83 |
Gross Profit | 313.27 | 305.3 | 363.12 | 313.66 | 574.54 | 525.42 |
Selling, General & Admin | 147.58 | 148.91 | 141.21 | 148.2 | 162.48 | 120.43 |
Research & Development | 46.63 | 45.6 | 53.05 | 47.81 | 72.35 | 58.29 |
Other Operating Expenses | 10.18 | 10.13 | 10.17 | 8.51 | 12.89 | 7.71 |
Operating Expenses | 207.81 | 208.06 | 208.95 | 204.17 | 250.32 | 189.4 |
Operating Income | 105.46 | 97.24 | 154.18 | 109.49 | 324.22 | 336.02 |
Interest Expense | -5.65 | -5.65 | -2.87 | -1.45 | -0.04 | -0.03 |
Interest & Investment Income | 17.84 | 17.84 | 30.99 | 17.67 | 15.01 | 20.63 |
Currency Exchange Gain (Loss) | -8.78 | -8.78 | 5.97 | -5.39 | 29.65 | -5.45 |
Other Non Operating Income (Expenses) | -5.71 | -0.38 | -0.28 | -0.23 | -0.41 | -1.53 |
EBT Excluding Unusual Items | 103.15 | 100.26 | 187.98 | 120.09 | 368.43 | 349.64 |
Impairment of Goodwill | -25.8 | -25.8 | -1.24 | -0.91 | - | - |
Gain (Loss) on Sale of Investments | -1.24 | -10.16 | 4.07 | - | -1.83 | - |
Gain (Loss) on Sale of Assets | 0.03 | -0.05 | -0.02 | -0.01 | -0.1 | 9.19 |
Asset Writedown | -2.16 | -0.35 | - | -1.69 | -1.48 | -2.29 |
Other Unusual Items | -1.06 | -1.06 | -2.06 | 1.74 | 5.66 | 4.2 |
Pretax Income | 72.91 | 62.83 | 188.74 | 119.23 | 370.67 | 360.73 |
Income Tax Expense | 16.85 | 11.46 | 17.23 | 10.1 | 44.63 | 49.74 |
Earnings From Continuing Operations | 56.06 | 51.38 | 171.5 | 109.13 | 326.04 | 310.99 |
Minority Interest in Earnings | 0.02 | 0.13 | 0.13 | - | - | - |
Net Income | 56.09 | 51.51 | 171.63 | 109.13 | 326.04 | 310.99 |
Net Income to Common | 56.09 | 51.51 | 171.63 | 109.13 | 326.04 | 310.99 |
Net Income Growth | -63.57% | -69.99% | 57.28% | -66.53% | 4.84% | 37.68% |
Shares Outstanding (Basic) | 220 | 224 | 220 | 221 | 220 | 220 |
Shares Outstanding (Diluted) | 220 | 224 | 220 | 221 | 220 | 220 |
Shares Change (YoY) | -1.14% | 1.77% | -0.61% | 0.82% | -0.20% | 23.76% |
EPS (Basic) | 0.25 | 0.23 | 0.78 | 0.49 | 1.48 | 1.41 |
EPS (Diluted) | 0.25 | 0.23 | 0.78 | 0.49 | 1.48 | 1.41 |
EPS Growth | -63.14% | -70.51% | 58.25% | -66.80% | 5.05% | 11.25% |
Free Cash Flow | 168.8 | 142.35 | 100.77 | 63.57 | 110.57 | 97.43 |
Free Cash Flow Per Share | 0.77 | 0.64 | 0.46 | 0.29 | 0.50 | 0.44 |
Dividend Per Share | 0.150 | 0.150 | 0.500 | 0.408 | 0.153 | 0.704 |
Dividend Growth | -70.00% | -70.00% | 22.49% | 166.62% | -78.26% | 7.33% |
Gross Margin | 27.01% | 26.88% | 32.56% | 32.17% | 39.12% | 44.00% |
Operating Margin | 9.09% | 8.56% | 13.83% | 11.23% | 22.07% | 28.14% |
Profit Margin | 4.84% | 4.54% | 15.39% | 11.19% | 22.20% | 26.04% |
Free Cash Flow Margin | 14.55% | 12.53% | 9.04% | 6.52% | 7.53% | 8.16% |
EBITDA | 191.07 | 184.45 | 247.79 | 193.48 | 364.88 | 357.54 |
EBITDA Margin | 16.47% | 16.24% | 22.22% | 19.84% | 24.84% | 29.94% |
D&A For EBITDA | 85.61 | 87.21 | 93.62 | 83.99 | 40.66 | 21.52 |
EBIT | 105.46 | 97.24 | 154.18 | 109.49 | 324.22 | 336.02 |
EBIT Margin | 9.09% | 8.56% | 13.83% | 11.23% | 22.07% | 28.14% |
Effective Tax Rate | 23.11% | 18.23% | 9.13% | 8.47% | 12.04% | 13.79% |
Revenue as Reported | 1,136 | 1,136 | 1,115 | 975.08 | 1,469 | 1,194 |
Advertising Expenses | - | 5.6 | 4.36 | 4.17 | 3.56 | 24.14 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.